Sanofi Unruffled By JAK Threat To Dupixent
As Blockbuster Hits €5.25bn In 2021 Sales
CEO Paul Hudson tells Scrip that in an atopic dermatitis market that has a standard of care like Dupixent, "it's hard to justify the role of a JAK unless somebody has, frankly, failed everything else."
You may also be interested in...
As the American Academy of Dermatology meeting ends in Boston, Scrip looks at some of the key data presented at the congress covering the latest advances in the hot area of atopic dermatitis, alopecia and butterfly skin.
The French drugmaker is pushing ahead with a listing of its Euroapi business on the Euronext in the next couple of months, in spite of the turbulence that the Russian invasion of Ukraine has brought to stock markets.
The French major has hit a rare roadblock in the onward march of its anti-inflammatory blockbuster.